AHA/ACC recommendations address broader spectrum of PAD care
Also finds PCSK9 inhibitor more potent than ezetimibe in statin-intolerant patients
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy